EP1263453A4 - Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere - Google Patents

Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere

Info

Publication number
EP1263453A4
EP1263453A4 EP01939971A EP01939971A EP1263453A4 EP 1263453 A4 EP1263453 A4 EP 1263453A4 EP 01939971 A EP01939971 A EP 01939971A EP 01939971 A EP01939971 A EP 01939971A EP 1263453 A4 EP1263453 A4 EP 1263453A4
Authority
EP
European Patent Office
Prior art keywords
regulating
biologically active
active compounds
polymer matrix
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01939971A
Other languages
German (de)
English (en)
Other versions
EP1263453A2 (fr
Inventor
Joachim B Kohn
Deborah M Schachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of EP1263453A2 publication Critical patent/EP1263453A2/fr
Publication of EP1263453A4 publication Critical patent/EP1263453A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01939971A 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere Ceased EP1263453A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US174137P 1999-12-31
PCT/US2001/000030 WO2001049249A2 (fr) 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere

Publications (2)

Publication Number Publication Date
EP1263453A2 EP1263453A2 (fr) 2002-12-11
EP1263453A4 true EP1263453A4 (fr) 2008-02-20

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01939971A Ceased EP1263453A4 (fr) 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere

Country Status (5)

Country Link
EP (1) EP1263453A4 (fr)
JP (1) JP2003519164A (fr)
AU (1) AU784226B2 (fr)
CA (1) CA2396037A1 (fr)
WO (1) WO2001049249A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326425B2 (en) 1999-12-31 2008-02-05 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1682537B1 (fr) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulateurs de l'adhesion cellulaire
ES2614080T3 (es) 2005-05-17 2017-05-29 Sarcode Bioscience Inc. Composiciones y métodos para el tratamiento de trastornos oculares
WO2009113972A2 (fr) 2006-02-08 2009-09-17 Tyrx Pharma, Inc. Prothèses de type treillis temporairement raidies
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
CA2667873A1 (fr) 2006-11-06 2008-10-23 Tyrx Pharma, Inc. Pochettes a mailles pour dispositifs medicaux implantables
EP2129339B1 (fr) 2007-03-29 2015-03-04 Tyrx, Inc. Enveloppes polymères biodégradables pour implants mammaires
WO2008137807A1 (fr) 2007-05-02 2008-11-13 Tyrx Pharma, Inc. Polymères de dihydroxybenzoate et leurs utilisations
EP2170930B3 (fr) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP3797775A1 (fr) 2007-10-19 2021-03-31 Novartis AG Compositions et procédés pour le traitement de la rétinopathie diabétique
WO2009139817A2 (fr) 2008-04-15 2009-11-19 Sarcode Corporation Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010006046A1 (fr) 2008-07-10 2010-01-14 Tyrx Pharma, Inc. Administration de médicaments anti-inflammatoires non stéroïdiens issus de polyarylates
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2833960C (fr) 2008-09-22 2015-12-22 Tyrx, Inc. Polyesteramides lineaires d'esters aminophenoliques
EP2437724B1 (fr) * 2009-06-01 2015-09-30 Tyrx, Inc. Compositions et méthodes pour prévenir les infections de blessures sternales
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
JP5956337B2 (ja) * 2009-07-31 2016-07-27 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 天然代謝産物のモノマー類似体から合成された生体吸収性ポリマー
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
WO2011050175A1 (fr) 2009-10-21 2011-04-28 Sarcode Corporation Agent pharmaceutique cristallin et procédés de préparation et utilisation de celui-ci
ES2713515T3 (es) 2010-08-25 2019-05-22 Tyrx Inc Recubrimientos novedosos para dispositivos médicos
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9585988B2 (en) 2010-11-12 2017-03-07 Tyrx, Inc. Anchorage devices comprising an active pharmaceutical ingredient
US9381281B2 (en) 2011-07-20 2016-07-05 Tyrx, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物
EP2958577A2 (fr) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Agonistes du recepteur de la guanylate cyclase pour l'utilisation dans l'irrigation du colon
WO2014137454A1 (fr) 2013-03-07 2014-09-12 Tyrx, Inc. Procédés et compositions permettant d'inhiber l'assemblage de cellules microbiennes se liant de façon irréversible à la surface de dispositifs médicaux
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
MY176976A (en) 2013-10-10 2020-08-28 Bausch Health Ireland Ltd Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2015069305A1 (fr) 2013-11-08 2015-05-14 Tyrx, Inc. Compositions antimicrobiennes et procédés de prévention d'infection dans des sites d'incision chirurgicale
EP3177319A1 (fr) * 2014-08-04 2017-06-14 Janssen Sciences Ireland UC Forme posologique solide comprimée
WO2017123634A1 (fr) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations et méthodes pour traiter la rectocolite hémorragique

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (fr) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymeres d'un polycarbonate a base de tyrosine et de poly(oxyde d'alkylene)
WO1998036013A1 (fr) * 1997-02-18 1998-08-20 Rutgers, The State University Monomeres derives d'acides hydroxyliques et polymeres prepares a partir de ceux-ci
WO1999024107A1 (fr) * 1997-11-07 1999-05-20 Rutgers, The State University Polymeres anioniques biodegradables derives de l-tyrosine aminoacide
WO1999029758A1 (fr) * 1997-12-12 1999-06-17 Samyang Corporation Poly[acide alpha-(omega-aminoalkyl) glycolique] pour le transport d'un agent bioactif par voie tissulaire et penetration cellulaire
WO1999052962A1 (fr) * 1998-04-13 1999-10-21 Rutgers, The State University Construction de bibliotheques de copolymeres

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
WO2000046854A1 (fr) * 1999-02-05 2000-08-10 Alien Technology Corporation Appareils et procedes de formation d'ensembles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (fr) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymeres d'un polycarbonate a base de tyrosine et de poly(oxyde d'alkylene)
WO1998036013A1 (fr) * 1997-02-18 1998-08-20 Rutgers, The State University Monomeres derives d'acides hydroxyliques et polymeres prepares a partir de ceux-ci
WO1999024107A1 (fr) * 1997-11-07 1999-05-20 Rutgers, The State University Polymeres anioniques biodegradables derives de l-tyrosine aminoacide
WO1999029758A1 (fr) * 1997-12-12 1999-06-17 Samyang Corporation Poly[acide alpha-(omega-aminoalkyl) glycolique] pour le transport d'un agent bioactif par voie tissulaire et penetration cellulaire
WO1999052962A1 (fr) * 1998-04-13 1999-10-21 Rutgers, The State University Construction de bibliotheques de copolymeres

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHA Y ET AL: "a one-week subdermal delivery system for l-methadone based on biodegradable microcapsules", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 1, April 1988 (1988-04-01), pages 69 - 78, XP002143620, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
WO2001049249A3 (fr) 2002-01-17
AU2925501A (en) 2001-07-16
JP2003519164A (ja) 2003-06-17
CA2396037A1 (fr) 2001-07-12
AU784226B2 (en) 2006-02-23
EP1263453A2 (fr) 2002-12-11
WO2001049249A2 (fr) 2001-07-12

Similar Documents

Publication Publication Date Title
EP1263453A4 (fr) Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere
AU5914999A (en) Controlled release drug delivery
HUP0301242A3 (en) Controlled release drug dosage form
IL132453A0 (en) Gastroretentive controlled release microspheres for improve drug delivery
AU2180400A (en) A pharmaceutical combination for the treatment of depression
IL121275A (en) Controlled release formulation for poorly soluble basic drugs
AU5335698A (en) Pharmaceutical formulations with delayed drug release
AU7839900A (en) Reusable medication delivery device
EP1251864A4 (fr) Formulation pharmaceutique composee d'un melange polymere et d'un compose actif pour une liberation regulee dans le temps
IL145581A0 (en) A modified release pharmaceutical composition comprising amoxycillin
AU4464897A (en) Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix
AU4328800A (en) Pharmaceutical formulation
AU2003240654A1 (en) Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
ZA988718B (en) Drug formulation having controlled release of active compound
IL134075A0 (en) Analgesic with controlled active substance release
AU5812800A (en) Pharmaceutical preparation
AU2773597A (en) Pharmaceutical compositions for the sustained release of insoluble active principles
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
AU5820900A (en) Capsule for the controlled release of active substances
AU5026599A (en) A wet granulation method for preparing a stable pharmaceutical formulation
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
IL148543A0 (en) Pharmaceutical carrier formulation
AU7887400A (en) A slow release pharmaceutical composition
AU3839900A (en) Pharmaceutical formulation
AU6866700A (en) Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020723

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

R17P Request for examination filed (corrected)

Effective date: 20020723

A4 Supplementary search report drawn up and despatched

Effective date: 20080121

17Q First examination report despatched

Effective date: 20080718

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110207